Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

211.55 UNCHANGED
Streaming Delayed Price Updated: 11:40 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
75 76 Next >
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why AbbVie Stock Was Cruising Higher on Thursday
The market was impressed with a notable increase in full-year guidance. 
Via The Motley Fool
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
AbbVie stock is the top trending ticker on Yahoo Finance Thursday earnings news has ABBV investors pumped up this morning. 
Via InvestorPlace
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
Exposures Economy
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and... 
Via Benzinga
Topics Earnings
Exposures Financial
AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance
The company's biggest drug, Humira, is about to give way to Skyrizi when it comes to sales power. 
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Is AbbVie the Best Dividend Stock for You?
The drug company has a famously strong dividend record -- and that looks set to continue. 
Via The Motley Fool
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
With political rumblings poised to make things exciting, investors may turn to the stability of trustworthy dividend stocks. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO. 
Via Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
10 Best Dividend Growth Stocks to Buy and Hold Forever
Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance. 
Via The Motley Fool
7 High-Yield Dividend Stocks to Help Pay Your Bills
It’s time to stop actively generating wealth and let your money work for you with high-yield dividend stocks to buy. 
Via InvestorPlace
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
3 Absurdly Cheap Stocks to Buy and Hold for Years
You can buy these solid stocks at some attractive discounts right now. 
Via The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Quantum AI Stocks That Could Redefine Computing
Three quantum AI stocks could shape the future of computing, which means current market prices are very cheap. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Recession-Proof Stocks to Shield Your Portfolio in 2024
Recession-proof stocks gain momentum as concerns about AI bubble grow and other factors contribute to needing to safeguard portfolios. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Spinoff Stocks You Should Buy Now: July 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies stand out for their pedigrees, robust financials, and future growth prospects. 
Via The Motley Fool
3 Dividend Growth Stocks to Buy and Hold
What's better than a dividend? A dividend that's growing. 
Via The Motley Fool
3 High-Yield Dividend Stocks That Still Look Like Bargains
The prices of these reliable dividend payers haven't kept pace with the frothy stock market. 
Via The Motley Fool
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.